Therapeutic Areas

Latest News

Image credit: Ban |
Four-Year Data from Long-Term Extension Trial Show Efficacy of Sotyktu Treating Moderate-to-Severe Plaque Psoriasis

May 17th 2024

Sotyktu (deucravacitinib; Bristol Myers Squibb) is an oral, selective, allosteric tyrosine kinase 2 inhibitor that produced clinically meaningful improvements in Psoriasis Area and Severity Index scores among adult patients with moderate-to-severe plaque psoriasis.

Image credit: 9dreamstudio |
Roche's Novel Dual GLP-1/GIP Receptor Agonist Produces Clinically Meaningful Weight Loss in Phase Ib Trial

May 16th 2024

Image credit: Dr_Microbe |
Eisai and Biogen Start Rolling Biologics License Application Submission to FDA for Subcutaneous Version of Alzheimer Disease Drug Leqembi

May 15th 2024

Image credit: Destina |
FDA Issues Complete Response Letter to sBLA for Four-Dose Heplisav-B Regimen in Adults on Hemodialysis

May 14th 2024

Image credit: JHVEPhoto |
FDA Delays Review of BLA Submission for Moderna's Novel Respiratory Syncytial Virus Vaccine

May 10th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.